The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...

A new study suggests AI can predict premature death among people who have inflammatory bowel disease, also known as Crohn's ...

Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...

A plant-based diet made up of mainly nutrient-dense plant foods, or an equally healthy omnivorous diet may help reduce the ...

A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...

New study shows that dysfunction of protective immune cells in GI tract may contribute to onset of inflammation in Crohn's disease.

In patients with Crohn's disease and intermediate to high preoperative corticosteroid use, primary ileocaecal resection leads ...

A team of scientists has discovered mechanisms of abnormal immune cell function that may lead to Crohn’s disease, an ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...